Hema Pharmaceuticals is committed to providing a well formulated Crisaborole medicine to its valuable clients. It is a novel oxaborole, a topical treatment of for mild to moderate atopic dermatitis. This non-steroidal agent is efficacious in improving the disease severity and reducing the risk of infection and signs and symptoms in patients 2 years old and older. This medication reduces the local inflammation in the skin and prevents further exacerbation of the disease. It is currently under development as a topical treatment of psoriasis.
Features of Crisaborole:
- Member of the class of benzoxaboroles
- A non-steroidal anti-inflammatory drug
- It is used to treat eczema
- It reduces swelling, redness, and itching